Stcube (052020)

Currency in KRW
15,590
+160(+1.04%)
Delayed Data·
052020 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
14,62015,850
52 wk Range
6,13022,500
Key Statistics
Bid/Ask
15,510.00 / 15,580.00
Prev. Close
15,430
Open
15,410
Day's Range
14,620-15,850
52 wk Range
6,130-22,500
Volume
255.61K
Average Volume (3m)
666.54K
1-Year Change
130.2806%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
052020 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Prominent player in the Electronic Equipment, Instruments & Components industry

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Neutral
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Mar 18, 2026
EPS / Forecast
-96.70 / --
Revenue / Forecast
2.74B / --
EPS Revisions
Last 90 days

052020 Income Statement

Compare 052020 to Peers and Sector

Metrics to compare
052020
Peers
Sector
Relationship
P/E Ratio
−49.9x3.0x12.8x
PEG Ratio
−1.790.010.01
Price/Book
15.1x2.8x2.4x
Price / LTM Sales
155.7x1.4x2.5x
Upside (Analyst Target)
-−1.2%18.4%
Fair Value Upside
Unlock1.5%0.5%Unlock

STCube, Inc., a biopharmaceutical company, develops medicines in South Korea. The company develops anti-cancer immunotherapeutic drugs and anti-viral drugs. It offers platform technologies, which include In vivo RNAi ICP target discovery platform for exploring material ICP target; glycosylation-specific antibody development platform for development of antibodies that mask glycosylation sites on target proteins; and ICP functional assay platform for development of various in vivo/in vitro analytical/experimental methods. The company’s product pipeline consists of various anti-cancer drugs, including anti PD-L1 Ab and anti PD-1 Ab in preclinical study, and anti STT-005 for solid tumor; anti STT-003 Ab in phase-1 for lung, head, and neck cancer; small molecule STT-011 inhibitor candidate development for pancreatic cancer; anti STT-012 Ab for breast and prostate cancer; and anti STT-013 Ab for solid tumor. The company was formerly known as Schem Co., Ltd. and changed its name to STCube, Inc. in April 2008. The company was founded in 1989 and is headquartered in Seoul, South Korea.

People Also Watch

1,705,000
009150
+8.46%
577,000
009155
+9.49%
1,118,000
011070
+4.68%
27,050
010170
-2.70%
27,075
047040
-8.06%

FAQ

What Is the Stcube (052020) Stock Price Today?

The Stcube stock price today is 15,590 KRW.

What Stock Exchange Does Stcube Trade On?

Stcube is listed and trades on the KOSDAQ.

What Is the Stock Symbol for Stcube?

The stock symbol for Stcube is "052020."

What Is the Stcube Market Cap?

As of today, Stcube market cap is 1.05T KRW.

What Is Stcube's Earnings Per Share (TTM)?

The Stcube EPS (TTM) is -321.

From a Technical Analysis Perspective, Is 052020 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Stcube Stock Split?

Stcube has split 2 times.

How Many Employees Does Stcube Have?

Stcube has 13 employees.

What is the current trading status of Stcube (052020)?

As of May 27, 2026, Stcube (052020) is trading at a price of 15,590 KRW, with a previous close of 15,430 KRW. The stock has fluctuated within a day range of 14,620 KRW to 15,850 KRW, while its 52-week range spans from 6,130 KRW to 22,500 KRW.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2026 - Fusion Media Limited. All Rights Reserved.